Helius Medical Q2 revenue up 115% YoY to $256K; net loss narrows to $1.6M

Solana Co

2023-Q2 EPS reported -$0.15 revenue$367,000

Q2 2023 revenue $256K vs $119K in Q2 2022 (+115%); PoNS sales driven by PTAP which ended June 30.
Net loss $1.6M ($0.06 per share) vs $3.8M ($0.97) prior year; operating loss $3.2M.
Cash $8.6M at June 30, 2023; no debt; cash burn $2.7M in Q2 (down $0.9M YoY).
PoNS device awarded DMEPOS accreditation by CMS-authorized TCT, a step toward Medicare reimbursement.
Guidance: Q3 and FY2023 revenue expected above prior year; U.S. sales to shift to cash-pay post-PTAP.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Solana Co reported the quarter ended June 30, 2023 results: revenue $256 thousand, net income $1.6 million, EPS $0.06 per share. Guidance initiated.

Period: the quarter ended June 30, 2023
Revenue: $256 thousand
Net income: $1.6 million
EPS: $0.06 per share
Guidance: initiated
Result: reported results

Exact text from the filing

Total revenue for the second quarter of 2023 was $256 thousand, an increase of $137 thousand compared to $119 thousand in the second quarter of 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Solana Co filing history →

Source: SEC EDGAR

accession 0001558370-23-014508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.